The FDA issued warning letters to 14 online marketers of ketamine. At the same time, the DEA is investigating what officials call “bad actors” prescribing the powerful anesthetic remotely. The concern is blunt: at-home misuse, and deaths tied to unmonitored use.
Ketamine is an anesthetic — a drug strong enough to put you under for surgery. It also showed real promise for depression. That promise is where this story starts.
How we got here
The backstory has a familiar American shape. First came a genuine medical breakthrough: ketamine’s promise for depression, delivered in clinics under a doctor’s eye.
Then came a delivery innovation. Telehealth — seeing a doctor by video instead of in person — exploded, and suddenly prescriptions could travel by mail.
Then came the business model, sprinting ahead of both. Online sellers found they could market a clinic drug to your couch. The couch, notably, does not come with a doctor.
Each step made sense on its own. Cheaper access to care is good. Fewer barriers for depressed patients is good. But three good ideas, stacked without a guardrail, added up to a powerful anesthetic arriving by mail.
Here is the problem in one sentence. When a drug’s safety profile depends on the room it is taken in, mailing it to the living room is not an innovation.
Why regulators moved
Supervision was never a nice-to-have with this drug. It was the entire point. A clinic can watch your blood pressure, your breathing, your state of mind. A shipping label cannot.
So the FDA wrote its letters, and the DEA started asking harder questions. Fourteen companies now get to explain their marketing to a federal agency. That is rarely a growth strategy.
This is what regulatory risk actually looks like. It does not arrive gradually. It arrives all at once, in an envelope with a government seal.
The investing lesson
For the Capital Wealth Growth Portfolio, this is a category lesson rather than a ticker. Regulatory risk concentrates exactly where growth outran oversight. The warning-letter wave marks the spot on the map.
The telehealth names that survive this cycle will be the ones whose economics never depended on prescribing the un-supervisable. If a company’s revenue requires doing the thing regulators exist to stop, the multiple does not matter. The business is renting time.
This is not a prediction that telehealth dies. Video visits for routine care are convenient, cheap, and here to stay. The line is narrower: it runs between convenience and supervision, and this drug sits on the wrong side of it.
Our own healthcare exposure — MRK, AMGN, REGN, UNH, and the XLV fund — lives on the other side of that line. Supervised, reimbursed medicine: drugs given the way regulators require, paid for by insurers on purpose.
That is the durable kind of healthcare revenue. It is slower. It is also still standing when the letters go out.
None of our positions are touched by this crackdown. That is not luck. Avoiding the neighborhood where growth outruns oversight is the point of owning boring, supervised medicine in the first place.